Portland, OR, Nov. 19, 2019 (GLOBE NEWSWIRE) -- The global Influenza Vaccine Market contributed $3.96 billion in 2018 and is projected to garner $6.20 billion by 2026, witnessing a CAGR of 5.9% from 2019 to 2026. The report provides a detailed analysis of changing market dynamics, key segments, top winning strategies, competitive landscape, and others.
An increase in prevalence of influenza, advancements in technologies regarding vaccine administration, and governments’ focus on immunization activities facilitate the growth of the global influenza vaccine market. However, high costs of vaccine development and strict regulatory scenario restrain the market growth. On the other hand, unexplored potential in the emerging nations and the introduction of vaccines offer various opportunities in the market.
Request Sample Report at https://www.alliedmarketresearch.com/request-sample/1437
On the basis of vaccine type, the quadrivalent segment accounted for around two-thirds of the total market share in 2018 and is expected to continue to lead throughout the forecast period. Moreover, this segment is expected to register the highest CAGR of 6.1% from 2019 to 2026. This is attributed to the cost-effectiveness and efficacy to provide better protection against viral strains. The study also explores the trivalent segment.
On the basis of technology, the cell-based segment is expected to grow at the largest CAGR of 6.5% from 2019 to 2026, owing to the elimination of contamination, cell banking facilities, and better protection as compared to traditional vaccines. However, the egg-based segment held the highest share of the global influenza vaccine market, contributing nearly nine-tenths of the total market share in 2018, and is expected to maintain its dominance throughout the forecast period.
Based on region, North America contributed the highest market share in 2018, contributing nearly half of the total market, and is estimated to contribute its highest share during the forecast period. However, LAMEA is estimated to register the largest CAGR of 7.5% from 2019 to 2026. This is attributed to better healthcare facilities and rise in pace of economic developments in this region.
For Purchase Enquiry at https://www.alliedmarketresearch.com/purchase-enquiry/1437
Leading market players analyzed in the report include
- AstraZeneca Plc.
- CSL Limited
- Biodiem
- F. Hoffmann-La Roche Ltd.
- Emergent BioSolutions
- GlaxoSmithKline Plc.
- Gamma Vaccines Pvt. Ltd.
- Novartis AG
- Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
- Sanofi Pasteur SA
- Pfizer, Inc.
- Sinovac Biotech Ltd.
Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree
Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.
Similar Reports:
Pneumonia Vaccine Market - Global Opportunity Analysis and Industry Forecast, 2018-2025
Rabies Vaccine Market - Global Opportunity Analysis and Industry Forecast, 2019-2026
Varicella Live Vaccine Market - Global Opportunity Analysis and Industry Forecast, 2018-2026
Metabolomics Market - Global Opportunity Analysis and Industry Forecast, 2017-2023
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.